MDxHealth (NASDAQ:MDXH) Issues Earnings Results

MDxHealth (NASDAQ:MDXH) announced its quarterly earnings results on Thursday. The company reported $999.00 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $999.13, reports. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 31.07%.The firm had revenue of $29.55 million for the quarter, compared to analysts’ expectations of $26.05 million.

Here are the key takeaways from MDxHealth’s conference call:

• Q4 billable volume was ~38,000 tests (up 62% YoY) with liquid tests up 128%, full-year revenue reported at $107.9M, and 2026 guidance implies roughly 28% growth to $137–$140M driven by unit growth rather than price.
• MDxHealth completed the Q4 transition of Select mdx customers to ExoDx, expects the ExoDx business to contribute $20M+ in 2026, and plans cross-selling after sales integration finishes in Q1.
• Short-term financial pressure: Q4 operating loss rose to $5.3M and net loss to $8.9M, adjusted EBITDA was -$2.1M, and cash on hand was $29M, with management attributing the weakness to integration-related OpEx.
• MDxHealth negotiated an amendment with Exact Sciences that lowers the upcoming earn-out by about $20M and defers full payment by a year, improving near-term liquidity and flexibility.
• Clinical progress: the GPS ProMPT study is complete and the landmark GPS‑ProtecT trial is commencing, which management says could support NCCN guideline adoption and strengthen long-term test adoption.

MDxHealth Stock Down 4.2%

NASDAQ:MDXH traded down $0.15 during midday trading on Friday, hitting $3.40. The company had a trading volume of 218,119 shares, compared to its average volume of 100,839. The stock’s fifty day moving average price is $3.55 and its 200-day moving average price is $3.75. The company has a market capitalization of $168.30 million, a PE ratio of -5.07 and a beta of 1.64. MDxHealth has a 52-week low of $1.35 and a 52-week high of $5.33.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on MDXH shares. Lake Street Capital upped their target price on shares of MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a research report on Monday, December 29th. TD Cowen increased their price objective on MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, BTIG Research reissued a “buy” rating and set a $7.00 price objective on shares of MDxHealth in a research note on Tuesday, December 23rd. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.75.

Institutional Investors Weigh In On MDxHealth

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Intesa Sanpaolo Wealth Management bought a new stake in shares of MDxHealth in the 4th quarter worth approximately $36,000. Lido Advisors LLC bought a new stake in MDxHealth in the third quarter worth $48,000. Squarepoint Ops LLC purchased a new stake in shares of MDxHealth in the fourth quarter worth $51,000. Jefferies Financial Group Inc. purchased a new stake in shares of MDxHealth in the third quarter worth $53,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of MDxHealth during the fourth quarter valued at $68,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.